William Willis, MD
General Practice · Poteau, OKNPI 1205875846
Payments from drug & device makers
Across 63 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$256
- GSK$126
- Portola Pharmaceuticals, LLC$103
- AstraZeneca$88
- Pfizer$78
- Exact Sciences$71
- plus $290 from 13 others
What the payments were for
- Food & beverage$1,012100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 20 | $256 |
| GSK | 8 | $126 |
| Portola Pharmaceuticals, LLC | 1 | $103 |
| AstraZeneca | 6 | $88 |
| Pfizer | 6 | $78 |
| Exact Sciences | 5 | $71 |
| Sanofi-aventis U.S. LLC | 3 | $49 |
| Sumitomo Pharma America, Inc. | 2 | $48 |
| Biohaven Pharmaceuticals, Inc. | 2 | $37 |
| Amarin Pharma, Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $18 |
| Novartis | 1 | $18 |
| Boston Scientific | 1 | $17 |
| Amgen | 1 | $16 |
| Novo Nordisk | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
| Abbott | 1 | $12 |
| Smith+Nephew | 1 | $12 |
| Axsome Therapeutics, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ANDEXXA$103
How this compares
$1,012 in reported general payments places this provider in the 80th percentile of 1,086 general practice providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 101 | $73,319 |
| OzempicSemaglutide | 46 | $58,265 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,545 | $49,178 |
| EliquisApixaban | 54 | $40,796 |
| Oxycodone Hcl | 627 | $16,845 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 35 | $16,477 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $12,700 |
| LinzessLinaclotide | 12 | $11,105 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $10,186 |
| MovantikNaloxegol Oxalate | 17 | $7,307 |
| FetzimaLevomilnacipran Hcl | 14 | $6,602 |
| SymbicortBudesonide/Formoterol Fumarate | 24 | $6,026 |
| GemtesaVibegron | 12 | $5,806 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 215 | $5,327 |
| MyrbetriqMirabegron | 11 | $5,036 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $126 | $96,204148 claims |
| Novo NordiskOzempic | $15 | $58,26546 claims |
| PfizerEliquis | $78 | $40,79654 claims |
| AbbVieLinzess, Fetzima, Synthroid | $256 | $19,31356 claims |
| Boehringer IngelheimCombivent Respimat | $18 | $16,47735 claims |
| AstraZenecaSymbicort | $88 | $6,02624 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $48 | $5,80612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,086 general practice providers in Oklahoma.
Other general practice in Poteau
- Vicki ConradEdmond$1.4M
- Wesley HodgeBroken Arrow$1.2M
- Joseph MassadTulsa$783K
- Ahmad MusaPauls Valley$462K
- Stephen BuchananOklahoma City$123K
- Jennie HunnewellOklahoma City$26K
- Kylie ParrishOklahoma City$19K
- Charles McQuiggJay$18K
- Sandy GraceOklahoma City$14K
- Justin EmamiTulsa$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.